# Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Study · id `cardio:ct-nct01415505` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01415505](<https://clinicaltrials.gov/study/NCT01415505>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01415505

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 812 participants.

## Technical summary

Registry record NCT01415505. Randomized; no masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 812 participants (enrolled count; ClinicalTrials.gov record NCT01415505, source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01415505, source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01415505, source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)
- Completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01415505, source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01415505, source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01415505-2013-06-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
- Condition: Hypertension
- Intervention (Drug): Nebivolol, Valsartan and Hydrochlorothiazide
- Lead sponsor: Forest Laboratories
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Forest Laboratories (`cardio:org-forest-laboratories`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study (`cardio:pubmed-25492835`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0c545a9b3eb3cc42bcbf64ecbc488f8e867798bd9c6ed1dc127a7ffd7fc8dc07
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
